Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-Directed Dosing of Captisol Enabled Melphalan in Multiple Myeloma or AL Amyloidosis
NCT02909036Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2016
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melphalan in multiple myeloma (MM) and Light-chain amyloidosis (AL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 1 day. Started Sep 2016; status: active, not recruiting.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)Light-chain amyloidosis (AL)
Beyond the preview
Go deeper on NCT02909036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909036.